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CC chemokine receptor 3 (CCR3), the sole receptor for eotaxins, is expressed on eosinophils and T helper type
2 (Th2) cells. In Hodgkin’s disease, eotaxin-1 secreted by fibroblasts collects Th2 cells and eosinophils within the
tissue. Similarly, many Th2 cells infiltrate the lesional skin of cutaneous T-cell lymphoma (CTCL). In this study,
we investigated the role of eotaxins in the development of the Th2 environment of CTCL. We revealed that
fibroblasts from lesional skin of CTCL expressed higher amounts of eotaxin-3 messenger RNA (mRNA)
compared with those from normal skin. Lesional skin of CTCL at advanced stages contained significantly higher
levels of eotaxin-3 and CCR3 mRNA, compared with early stages of CTCL. IL-4 mRNA was expressed in some
cases at advanced stages. Immunohistochemistry revealed that keratinocytes, endothelial cells, and dermal
fibroblasts in lesional skin of CTCL showed a stronger expression of eotaxin-3 than did normal skin. CCR3þ
lymphocytes and IL-4 expression were observed in some cases of advanced CTCL. Furthermore, both serum
eotaxin-3 and eotaxin-1 levels of CTCL patients at advanced stages were significantly higher than those of
healthy individuals. The concentrations of these chemokines correlated with serum soluble IL-2 receptor levels.
These results suggest that interaction of eotaxins and CCR3 regulates the Th2-dominant tumor environment,
which is closely related to the development of CTCL.
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INTRODUCTION
Mycosis fungoides (MF) and Se´zary syndrome (SS) are the
most common types of cutaneous T-cell lymphoma (CTCL;
Willemze et al., 2005). MF has a classically prolonged
clinical course that progresses over years through patch,
plaque, and tumor stages, followed by lymph node and
visceral involvement. SS is characterized by fever, erythro-
derma, lymphadenopathy, and leukemic involvement, and
usually has a rapid clinical course. Patients with CTCL
frequently show eosinophilia and high levels of serum IgE.
Serum levels of thymus and activation-regulated chemokine,
a chemokine that induces infiltration of T helper type 2 (Th2)
cells, are elevated in advanced stages of CTCL (Kakinuma
et al., 2003). Th2 cytokine messenger RNA (mRNA) is
detected in the skin of patients with CTCL (Vowels et al.,
1994). Clonal T cells in SS transcribe and secrete mainly Th2
cytokines (Dummer et al., 1996). In addition, more Th2 cells
expressing CC chemokine receptor 4 (CCR4) infiltrate the
lesional skin of CTCL as the disease progresses (Kakinuma
et al., 2003; Yagi et al., 2006). The Th2-dominant environ-
ment is beneficial for tumor cells because IFN-g-producing
Th1 cells augment antitumor immune responses. Indeed,
IFN-g has proved to be effective for CTCL (Kaplan et al.,
1990). Gene therapy approaches using adenoviruses
encoding IFN-g have been used successfully in CTCL
(Urosevic et al., 2007).
Both eotaxin-3 and eotaxin-1 belong to the CC chemokine
family and have potent chemotactic activity for CCR3þ cells
such as eosinophils (Forssmann et al., 1997), basophils
(Uguccioni et al., 1997), and subpopulations of Th2 cells
(Sallusto et al., 1997). Eotaxin-1 protein is upregulated in
various inflammatory diseases that are characterized by
massive infiltration of eosinophils, such as allergic asthma
(Ganzalo et al., 1996; Campbell et al., 1998), allergic rhinitis
(Baraniuk, 1997), and atopic dermatitis (Yawalkar et al.,
1999; Kaburagi et al., 2001), and is thought to be a key player
in the pathogenesis of these conditions. In addition, eotaxin-1
mRNA is upregulated within tissues involved in lymphoma
isolated from patients with Hodgkin’s disease (Teruya-
Feldstein et al., 1999). Eotaxin-1 was strongly expressed in
fibroblasts from Hodgkin’s disease patients (Jundt et al.,
1999). Eotaxin-1 was also reported to be expressed by tumor
cells of cutaneous anaplastic large-cell lymphoma (Kleinhans
et al., 2003). The tumor cells also expressed CCR3,
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suggesting that eotaxin-1 functions in an autocrine manner in
this type of lymphoma. Thus far, there have been no reports
investigating the role of eotaxin-1 in MF and SS.
Eotaxin-3, a new member of the eotaxin family, was
cloned after identification of eotaxin-1 and eotaxin-2 (Shinkai
et al., 1999). Eotaxin-3 may also have an important role in
allergic diseases such as atopic dermatitis and allergic
asthma, similar to eotaxin-1 (Berkman et al., 2001; Kagami
et al., 2003). There have been no reports on the expression of
eotaxin-3 in any type of lymphoma.
In this study, we investigated possible roles of eotaxin-3
and -1 in the Th2-dominant environment of CTCL. We have
found that dermal fibroblasts, keratinocytes (KCs), and
endothelial cells in lesional skin of CTCL contribute to the
elevation of eotaxin-3 expression, resulting in an increased
chemotaxis of CCR3þ cells into tumors. IL-4, a representative
Th2 cytokine, was expressed in some cases of advanced
stages of CTCL, suggesting that a Th2 cell–rich environment
was actually present in these patients. Furthermore, both
serum eotaxin-3 and eotaxin-1 levels of patients with
CTCL were closely associated with disease activity and
treatment effect. The results of this study suggest that
eotaxin and CCR3 interaction regulates the Th2-dominant
tumor environment, which is closely related to the develop-
ment of CTCL.
RESULTS
Eotaxin-3, CCR-3, and IL-4 mRNA expression of lesional skin in
CTCL and of normal skin
Dermal fibroblasts express eotaxin-3 (Hoeck and Woisets-
chla¨ger, 2001) and eotaxin-1 (Miyamasu et al., 1999)
proteins in the presence of IL-4 and tumor necrosis factor-a,
whereas HaCaT cells, a KC cell line, express eotaxin-3
protein in the presence of IL-4 (Kagami et al., 2005). We first
confirmed that human fibroblasts and KCs expressed these
chemokines. When fibroblasts were stimulated with IL-4,
mRNA expression of eotaxin-3 and eotaxin-1 was increased
(Figure 1a). When HaCaT cells were stimulated with IL-4,
eotaxin-3 mRNA expression was increased in a dose-
dependent manner, whereas eotaxin-1 mRNA expression
was not detected (data not shown). These results were
consistent with previous reports (Miyamasu et al., 1999;
Hoeck and Woisetschla¨ger, 2001; Kagami et al., 2005).
To investigate the production of eotaxin-3 and eotaxin-1
by fibroblasts from CTCL lesional skin, we isolated human
dermal fibroblasts from lesional skin of CTCL and from
normal skin. After several passages, we stimulated fibroblasts
with IL-4 in vitro and examined mRNA levels of eotaxin-3
and eotaxin-1 by quantitative reverse transcriptase PCR (RT-
PCR). There was no significant difference between nonsti-
mulated fibroblasts from lesional skin of CTCL and those from
normal skin with regard to the mRNA expression levels of
these chemokines. IL-4-stimulated fibroblasts from CTCL,
however, expressed much more eotaxin-3 mRNA than those
from normal skin (B10-fold, Po0.01; Figure 1a). Eotaxin-1
mRNA expression by fibroblasts from lesional skin of CTCL
was slightly higher (approximately threefold) than that from
normal skin, although the difference was not statistically
significant. Thus, the production of eotaxin-3 and eotaxin-1
by fibroblasts in CTCL lesional skin was enhanced.
We next assessed eotaxin-3, IL-4, and CCR3 mRNA
expression in lesional skin of CTCL and in normal skin.
Lesional skin in early stages (patch and plaque) contained less
eotaxin-3 mRNA as compared with normal skin, consistent
with previous papers suggesting Th1 dominancy in early
stages of CTCL (Papadavid et al., 2003; Chong et al., 2008).
Lesional skin of CTCL at advanced stages (tumor and
erythroderma) contained significantly higher levels of eotax-
in-3 and CCR3 mRNA as compared with early stages of CTCL
(Figure 1b). IL-4 mRNA expression was detected in some
cases at advanced stages. Significant correlations were found
between eotaxin-3 and IL-4, eotaxin-3 and CCR3, and IL-4
and CCR3 (Figure 1c). Thus, these results suggest that an
enhanced eotaxin-3 expression induced by IL-4 in lesional
skin of CTCL results in increased chemotaxis of CCR3þ cells
into tumors.
Immunohistochemistry of eotaxin-3, CCR3, and IL-4 in lesional
skin of CTCL and in normal skin
We next immunolabeled samples of lesional skin of CTCL
and normal skin for eotaxin-3, eotaxin-1, CCR3, and IL-4. In
normal skin, epidermal KCs, dermal fibroblasts, and dermal
endothelial cells expressed eotaxin-3 (Figure 2a). CCR3 was
expressed by epidermal KCs and fibroblasts (Figure 2e).
Eotaxin-1 and IL-4 were not detected (Figure 2g and data not
shown). In lesional skin of CTCL, expression of eotaxin-3 was
stronger than that observed in normal skin (Figure 2b).
Among 12 patients with CTCL (patch: 2, plaque: 3, tumor: 3,
and erythroderma: 4), lesional skin of patients with tumor or
erythroderma showed a stronger expression of the chemokine
(Table 1). By contrast, eotaxin-1 expression was not detected
by immunohistochemistry in either normal skin or skin
affected by CTCL (data not shown). Similar results were
obtained when frozen samples were used (data not shown).
In one SS and one MF patient, we immunolabeled skin for
eotaxin-3 before and after treatment. After treatment with
topical corticosteroids and UV phototherapy, skin lesions
were almost cleared. Expression of eotaxin-3 in skin
decreased after treatment (Figure 2c and d). Various numbers
of CCR3þ lymphocytes were observed in cases of CTCL
(Figure 2f). IL-4 was expressed in some cases of advanced
stages of CTCL (Figure 2h), which was consistent with mRNA
expression.
Increased levels of serum eotaxin-3 and eotaxin-1 in patients
with CTCL
We next measured serum eotaxin-3 and eotaxin-1 levels in
patients with CTCL and in healthy controls. Serum eotaxin-3
levels in patients with CTCL were 21.5±18.0 pg ml1,
whereas those in healthy individuals were 11.0±2.5 pg ml1
(P¼0.08). Considering only patients at the plaque, tumor,
and erythroderma stages of CTCL, serum levels of eotaxin-3
were significantly higher (31.5±20.8 pg ml1) than those in
healthy controls. In patients with CTCL at the patch stage
(n¼22), plaque stage (n¼ 8), and tumor stage (n¼5), and
with erythroderma (n¼5), the serum eotaxin-3 levels were
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13.3±9.7, 25.5±22.5, 32.1±17.0, and 40.4±22.4 pg ml1,
respectively (Figure 3a). The levels in patients at the plaque,
tumor, and erythroderma stages were significantly higher
than those in controls (Po0.05, 0.01, and 0.01, respectively).
They were also significantly higher than the levels in patients
at the patch stage (Po0.05, 0.05, and 0.01, respectively).
The serum eotaxin-1 levels in patients with CTCL were
156.0±67.8 pg ml1, which were significantly higher than
those in controls (121.0±50.0 pg ml1, Po0.05). Consider-
ing only patients at the plaque, tumor, and erythroderma
stages, the serum levels of eotaxin-1 were much higher
(182±20.8 pg ml1) than those in healthy individuals.
In CTCL at the patch, plaque, tumor, or erythroderma stage,
the serum eotaxin-1 levels were 134.0±68.4, 185.7±69.6,
187.0±35.2, and 172.3±58.1 pg ml1, respectively (Figure
3b). The levels in patients at the plaque, tumor, and
erythroderma stages were significantly higher than those in
controls (Po0.05, 0.05, and 0.05, respectively). The levels in
patients with tumor stage were slightly higher than those
in patients at the patch stage (P¼0.06).
In three patients with CTCL (two men and one woman, age
range 44–64 years, all cases with MF), we measured serum
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Figure 1. Eotaxin-3, CC chemokine receptor 3 (CCR3), and IL-4 messenger RNA (mRNA) expression of lesional skin of cutaneous T-cell lymphoma (CTCL) and
of normal skin. (a) Human dermal fibroblasts from lesional skin of CTCL or from normal skin were cultured in round-bottomed six-well plates with medium only
or with IL-4 (10 ng ml1). Total RNA was extracted from fibroblasts, and quantitative reverse transcriptase PCR (RT-PCR) was performed to measure eotaxin-3
and eotaxin-1 expression relative to glyceraldehyde-3-phosphate dehydrogenase. The measured values from individual patients are plotted by dots. *Po0.05.
(b) Eotaxin-3, CCR3, and IL-4 mRNA expression in lesional skin of CTCL and in normal skin was assessed by quantitative RT-PCR. *Po0.05, **Po0.01. (c)
Correlations between eotaxin-3, CCR3, and IL-4 mRNA expression levels in lesional skin of CTCL.
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eotaxin-3 and eotaxin-1 levels before and after treatment. The
treatment included topical and oral corticosteroids, UV
phototherapy, electron beam, oral etretinate, and/or systemic
IFN-g. All cases, at least temporarily, showed clearance of
skin lesions. After treatment, the serum eotaxin-3 and
eotaxin-1 levels decreased from 51.4±25.6 and 177.0±
43.8 pg ml1 to 25.7±28.2 and 115.9±55.0 pg ml1,
respectively, which correlated with the improvement in skin
condition (Figure 3c). In addition, in four patients with CTCL
(three men and one woman, age range 56–75 years, three
cases with MF and one case with SS), we measured eotaxin-3
and eotaxin-1 levels before and after disease progression.
Despite aggressive therapy, such as topical and oral
corticosteroids, UV phototherapy, electron beam, oral
etretinate, oral chemotherapy (cyclophosphamide or metho-
trexate), and/or CHOP (cyclophosphamide, hydroxydaunor-
ubicin, oncovin, and prednisolone), skin lesions continued
to progress in these four individuals. The average serum
eotaxin-3 and eotaxin-1 levels increased from 14.1±9.5 and
130.3±40.3pg ml1 to 29.8±10.8 and 232.3±108.6 pg ml1,
respectively, after progression of skin lesions (Figure 3d). The
changes in serum eotaxin-3 and eotaxin-1 levels (Figure 3c
and d) were not associated with the kind of treatment used
(data not shown).
Correlation between serum levels of eotaxins and serum sIL-2R
levels in patients with CTCL
We compared serum eotaxin-3 and eotaxin-1 levels with
other clinical and laboratory data: age, sex, and serum levels
of lactate dehydrogenase (LDH), IgE, and soluble IL-2
receptor (sIL-2R). We first found that serum eotaxin-3 levels
and serum eotaxin-1 levels significantly correlated with each
other (r¼0.56, Po0.01; Figure 4a). Serum eotaxin-3 levels
also correlated with serum LDH and sIL-2R levels (r¼0.41,
Po0.05 and r¼0.53, Po0.01, respectively; Figure 4b and c).
Serum eotaxin-1 levels correlated with serum sIL-2R levels
(r¼0.54, Po0.01; Figure 4d). Other factors, including the
number of eosinophils in peripheral blood, were not
correlated with serum eotaxin-3 or eotaxin-1 levels (data
not shown). Multivariate analysis with serum levels of sIL-2R,
LDH, eotaxin-3, and eotaxin-1 revealed that only sIL-2R and
eotaxin-3 were independent predictors of survival (data not
shown). These results suggest that serum levels of eotaxins,
especially that of eotaxin-3, can be a useful disease marker
for CTCL.
DISCUSSION
In this study, we have revealed that cultured fibroblasts
isolated from lesional skin of CTCL express higher amounts of
eotaxin-3 mRNA as compared with those from normal skin.
Lesional skin of CTCL at advanced stages contains more
eotaxin-3 and CCR3 mRNA as compared with that of early
CTCL. IL-4, a representative Th2 cytokine, was expressed in
some cases of advanced stages of CTCL, suggesting that a Th2
cell–rich environment was actually present in these patients.
KCs and endothelial cells, as well as dermal fibroblasts, in
lesional skin of CTCL show a stronger expression of eotaxin-3
than those in normal skin. Furthermore, both serum eotaxin-3
and eotaxin-1 levels in patients with CTCL at advanced stages
are significantly higher than those in healthy individuals.
The concentrations of these chemokines correlate with serum
sIL-2R levels, also showing significant correlation with
disease activity. The results of this study suggest that eotaxins
and CCR3 interaction regulates the Th2-dominant tumor
environment, which is closely related to the development
of CTCL.
Eotaxin-3 is reported to be expressed by epidermal KCs
(Nishi et al., 2008), dermal fibroblasts (Hoeck and Woisets-
chla¨ger, 2001), and endothelial cells (Shinkai et al., 1999).
Eotaxin-1 is expressed by dermal fibroblasts (Miyamasu et al.,
Before treatment (CTCL)
Normal skin
Normal skin
CTCL
CTCL
After treatment (CTCL)
Eotaxin-3
Eotaxin-3
CCR3
IL-4
Normal skin CTCL
Figure 2. Immunohistochemistry of eotaxin-3, CC chemokine receptor 3
(CCR3), and IL-4 in lesional skin of CTCL and in normal skin. (a) Staining of
normal skin for eotaxin-3. Epidermal keratinocytes, dermal fibroblasts, and
dermal endothelial cells expressed eotaxin-3. (b) Staining of lesional skin in
patients with CTCL for eotaxin-3. In lesional skin of CTCL, eotaxin-3
expression was stronger than observed in normal skin. (c, d) Staining of skin
for eotaxin-3 in a patient with CTCL before (c) and after (d) treatment.
Expression of eotaxin-3 decreased after treatment. (e) Staining of normal skin
for CCR3. Epidermal keratinocytes and dermal fibroblasts expressed CCR3. (f)
Staining of lesional skin in patients with CTCL for CCR3. A moderate number
of dermal-infiltrating lymphocytes expressed CCR3. (g, h) Staining for IL-4 in
normal skin (g) and lesional skin of CTCL (h). IL-4 was expressed by dermal-
infiltrating lymphocytes in CTCL (arrowheads). Bar¼ 200mm for a–d, and
100mm for e–h.
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Table 1. Results of immunohistochemical analysis of eotaxin-3 and IL-4 and real-time RT-PCR of eotaxin-3, IL-4,
and CCR3 in 12 CTCL patients
Immunohistochemistry Real-time RT-PCR
Age Sex Stage Eotaxin-3 IL-4 Eotaxin-3 IL-4 CCR3
54 M Patch ±  5.53 104 7.04103 4.84 103
49 M Patch ±  1.09 103 ND 8.73 103
63 M Plaque +  8.27 104 3.13104 2.09 103
64 M Plaque +  4.33 103 ND ND
56 F Plaque ++  2.23 102 3.80103 3.98 103
45 M Tumor +  1.48 102 ND 1.88 102
65 F Tumor ++  2.19 102 ND 8.20 103
60 F Tumor +++ ++ 2.38 101 8.83102 4.97 101
58 F Erythroderma +++  3.17 102 1.20105 1.05 102
40 M Erythroderma ++ + 1.83 101 2.93101 6.16 102
33 F Erythroderma ++ + 3.30 101 8.41101 3.12 101
64 F Erythroderma ++ + 4.06 101 1.41101 1.68 101
Abbreviations: CCR3, CC chemokine receptor 3; CTCL, cutaneous T-cell lymphoma; F, female; M, male; ND, not detected; RT-PCR, reverse
transcriptase PCR.
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Figure 3. Serum levels of eotaxin-3 and eotaxin-1 in patients with cutaneous T-cell lymphoma (CTCL) and in healthy controls. (a) Serum eotaxin-3 levels in
patients with CTCL and in healthy controls. The measured values from individual patients are plotted by dots. Data are presented as mean±SD. *Po0.05,
**Po0.01. (b) Serum eotaxin-1 levels in patients with CTCL and in healthy controls. The measured values from individual patients are plotted as dots. Data are
presented as mean±SD. *Po0.05. (c) Serum eotaxin-3 (left) and eotaxin-1 (right) levels before and after treatment of CTCL. (d) Serum eotaxin-3 (left) and
eotaxin-1 (right) levels before and after progression of skin lesions of CTCL.
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1999), endothelial cells (Rothenberg et al., 1995), and dermal
dendritic cells (Beaulieu et al., 2002). In this study, we
showed that dermal fibroblasts from lesional skin of CTCL,
stimulated with IL-4, expressed significantly more eotaxin-3
and slightly more eotaxin-1 than those from normal skin. It is
known that fibroblasts isolated from diseased skin maintain
cellular characteristics even after isolation and in vitro culture
(Asano et al., 2004). IL-4 is reported to be abundantly
expressed by lesional skin of CTCL (Vowels et al., 1994). We
also showed IL-4 expression in lesional skin, at least in some
cases of advanced CTCL (Figure 1b and 2h). Furthermore,
tumor clones of CTCL express IL-4 (Echchakir et al., 2000).
These results suggest that dermal fibroblasts in lesional skin,
stimulated with IL-4 expressed by tumor cells, contribute
to the elevation of eotaxin-3 and eotaxin-1 in patients
with CTCL.
Immunohistochemistry showed that epidermal KCs and
endothelial cells as well as dermal fibroblasts expressed
eotaxin-3, consistent with previous reports (Hoeck and
Woisetschla¨ger, 2001; Kleinhans et al., 2003; Nishi et al.,
2008). However, we could not confirm eotaxin-1 expression
in the skin by immunohistochemistry, probably because of
sensitivity issues. Lesional skin from CTCL patients showed
stronger expression of eotaxin-3 than did normal skin, and
eotaxin-3 expression in lesional skin from two cases of CTCL
decreased after treatment (Figure 2a–d). These results suggest
that enhanced expression of eotain-3 is associated with
development of CTCL.
Most tumor cells in MF and SS are reported to be negative
for CCR3, the sole receptor for eotaxins (Kallinich et al.,
2003; Kleinhans et al., 2003). Judging from the data for an SS
patient, we did not suppose that tumor cells expressed CCR3
because the frequency of Se´zary cells in PBMC was much
higher than that of CCR3þ cells (data not shown). Therefore,
it is unlikely that high expression levels of eotaxins in patients
with CTCL have a direct effect on tumor cells. It is possible,
however, that eotaxins have important roles in establishing
the tumor microenvironment. We showed an elevated
expression of CCR3 mRNA in lesional skin of advanced
CTCL (Figure 1b). We also showed CCR3þ lymphocytes in
lesional skin of CTCL. It is likely that CCR3þ lymphocytes
were induced to migrate into lesional skin by eotaxins, as
there was significant correlation between eotaxin-3 and
CCR3 expression in lesional skin of CTCL (Figure 1c). Judging
from immunohistochemistry, CCR3þ lymphocytes were
CD3þCD4þCD8, the staining pattern of which was the
same as that of tumor cells of CTCL (data not shown). Real-
time RT-PCR and immunohistochemical study showed that
expression of IL-4 was much stronger when more CCR3þ
lymphocytes infiltrated into the lesional skin (Figure 1c and
Table 1). IL-4 was expressed by both CCR3þ lymphocytes
and CCR3 tumor cells. We believe that an interaction
between CCR3þ lymphocytes and CCR3 tumor cells is
important for optimized IL-4 production and establishment
of a Th2-dominant microenvironment for the survival of
tumor cells.
In this study, serum levels of eotaxin-3 and eotaxin-1 were
significantly elevated in patients with advanced stages of
CTCL. The value ranges were comparable to those in patients
with atopic dermatitis (Kaburagi et al., 2001; Kagami et al.,
2003).The values for patch-stage patients were clustered
around the values for normal controls. This is true for other
disease-related chemokines such as thymus- and activation-
regulated chemokines and cutaneous T-cell-attracting che-
mokines (Kakinuma et al., 2003; Kagami et al., 2006). Serum
eotaxin-3 levels were significantly correlated with serum
LDH and sIL-2R levels, which are reported to reflect the
disease activity of CTCL (Martı´ et al., 1991; Zachariae et al.,
1991; Wasik et al., 1996). Serum eotaxin-1 levels were also
significantly correlated with serum sIL-2R levels. In addition,
serum eotaxin-3 and eotaxin-1 levels in patients with CTCL
decreased after treatment and increased after progression of
skin lesions. Our results strongly indicate that serum eotaxin-
3 and eotaxin-1 levels correlate with disease activity in CTCL.
Indeed, multivariate analysis with serum levels of sIL-2R,
LDH, eotaxin-3, and eotaxin-1 revealed that only sIL-2R and
eotaxin-3 were independent predictors of survival (data
not shown). In conclusion, this study has revealed that
interaction of eotaxins and CCR3 controls the Th2-dominant
tumor environment, which may contribute to the develop-
ment of CTCL. Targeting this interaction may be another
strategy for destroying the Th2-dominant microenvironment
of CTCL, thus making tumor cells vulnerable to Th1
immune cells.
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Figure 4. Correlations between serum eotaxin-3 or eotaxin-1 levels in
patients with cutaneous T-cell lymphoma (CTCL) and other laboratory data.
(a) Correlations between serum eotaxin-3 levels and serum eotaxin-1 levels.
(b) Correlations between serum eotaxin-3 levels and serum lactate
dehydrogenase (LDH) levels. (c) Correlations between serum eotaxin-3 levels
and serum soluble IL-2 receptor (sIL-2R) levels. (d) Correlations between
serum eotaxin-1 levels and serum sIL-2R levels.
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MATERIALS AND METHODS
Serum and tissue samples
Forty patients with CTCL (36 MF cases and 4 SS cases; mean±
standard deviation age: 57.9±13.5 years, 22 men and 18 women)
and 20 healthy control subjects (44.7±17.3 years, 13 men and 7
women) were enrolled in this study. mRNA was obtained from
biopsy samples of lesional skin of patients with CTCL (n¼ 17, patch:
3, plaque: 5, tumor: 5, and erythroderma: 4) and from normal
skin (n¼ 7) using an Illustra QuickPrep Micro mRNA Purification Kit
(GE Healthcare, Buckinghamshire, UK). All samples were collected
during daily clinical practice. Serum samples were collected
from almost all patients with lymphoma in our facilities; other
samples were obtained from selected cases that were available. The
medical ethics committee of the University of Tokyo approved all
described studies, and the study was conducted according to the
Declaration of Helsinki Principles. Informed consent was obtained
to use blood and skin samples from patients and healthy controls. All
patients with CTCL were given diagnoses according to the World
Health Organization–European Organization for Research and
Treatment of Cancer classification for cutaneous lymphomas (Will-
emze et al., 2005). Disease extent was classified by type of skin
lesion (patch, plaque, tumor, and erythroderma). We collected sera
before and after treatment from three patients with MF, and sera
before and after progression from three MF patients and one SS
patient. We collected the sera at the first visit of the patients and used
them as the ‘‘before’’ samples. The 20 healthy controls had no
history of allergy, psoriasis, or CTCL. All serum samples were stored
at 20 1C until use.
Enzyme-linked immunosorbent assay
Immunoreactive eotaxin-3 and eotaxin-1 in sera and plasma were
quantified using the human eotaxin-3 ELISA kit and the human
eotaxin-1 ELISA kit (R&D Systems, Minneapolis, MN). These assays
employ the quantitative sandwich enzyme immunoassay technique.
Optical densities were measured at 450 nm using a Bio-Rad Model
550 microplate reader (Bio-Rad Laboratories, Hercules, CA). The
concentrations were calculated from a standard curve generated by a
curve-fitting program. The measured values from individual patients
were plotted using dots.
Immunohistochemistry
We performed immunohistochemical staining for eotaxin-3, eotaxin-1,
CCR3, and IL-4 with lesional skin of patients with CTCL (n¼ 12,
patch: 2, plaque: 3, tumor: 3, and erythroderma: 4) and with normal
skin (n¼ 2). In one SS patient and one MF patient, we performed
immunohistochemical staining for eotaxin-3 and eotaxin-1 with skin
before and after treatment. Briefly, 5-mm-thick tissue sections from
formaldehyde-fixed and paraffin-embedded samples were dewaxed
and rehydrated. In some experiments, skin samples were snap
frozen, cut into 5-mm-thick cryostat sections, and fixed in acetone.
These sections were then stained with mouse anti-human eotaxin-3
mAbs, mouse anti-human eotaxin-1 mAbs (R&D Systems), rabbit
anti-human CCR3 mAbs (MBL International, Woburn, MA), mouse
anti-human IL-4 mAbs (Santa Cruz Biotechnology, Santa Cruz, CA),
or mouse IgG, followed by ABC staining (Vector Laboratories,
Burlingame, CA). Diaminobenzidine or alkaline phosphatase was
used for visualizing the staining and counterstaining with Mayer
hematoxylin was performed according to the manufacturers’
instructions. The positivity of staining was ranked from  to
þ þ þ , as shown in Table 1.
Cell culture
Human adult dermal fibroblasts were grown from explants of
lesional skin biopsy samples from five patients with CTCL. Control
fibroblasts were obtained from five healthy donors during minor
surgery for unrelated reasons. The cells were cultured in 75 cm2 cell
culture flasks (Corning, Corning, NY) at 37 1C, 5% CO2 in Eagle’s
minimum essential medium (Sigma, St Louis, MO) containing 10%
fetal bovine serum, penicillin G sodium, streptomycin sulfate, and
amphotericin B. Third- to fourth-passage cells were used in all
experiments. HaCaT cells were cultured in a manner similar to that
for fibroblasts. Fourteenth- to seventeenth-passage cells were used in
all experiments.
Stimulation of cells
When confluence of the 75 cm2 cell culture flask was achieved,
HaCaT cells or human adult dermal fibroblasts were trypsinized,
washed, and resuspended in Eagle’s minimum essential medium
with 10% fetal bovine serum at 1 106 cells per ml, and 1 ml of cells
was added to each well of the six-well plates (Becton Dickinson,
Franklin Lakes, NJ). When the cells reached semiconfluence, the
medium was replaced with 1 ml Eagle’s minimum essential medium
without fetal bovine serum. HaCaT cells were stimulated with
recombinant IL-4 (R&D Systems). Human adult dermal fibroblasts
were stimulated with recombinant IL-4. After 24 hours, the cells
were harvested for quantitative real-time PCR. Total RNA from cells
was prepared using TRIZOL Reagent (Invitrogen, Carlsbad, CA).
Real-time quantitative RT-PCR assay
cDNA was synthesized using TaqMan Reverse Transcription
Reagents (Applied Biosystems, Foster City, CA). Quantitative RT-
PCR was performed as described previously (Sugaya et al., 2006).
Primers for human eotaxin-3, eotaxin-1, CCR3, IL-4, and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) were as follows:
eotaxin-3 forward, 50-TCTGTACCCATCCAAGGAAAA-30 and re-
verse, 50-GGGTCCATGTAGCCTTCAGA-30; eotaxin-1 forward, 50-
GGGCCAGCTTCTGTCCCAAC-30 and reverse, 50-TTATGGCTTTGG
AGTTGGAGATTT-30; CCR3 forward, 50-TCGTTCTCCCTCTGCTCG
TT-30 and reverse, 50-GCCGGATGGCCTTGTACTTT-30 IL-4 forward,
50-CACAGGCACAAGCAGCTGAT-30 and reverse, 50-CTCTGGTT
GGCTTCCTTCACA-30; GAPDH forward, 50-ACCCACTCCTCCAC
CTTTGA-30 and reverse, 50-CATACCAGGAAATGAGCTTGACAA-30.
Statistical analysis
Statistical analysis between two groups was performed using the
Mann–Whitney U-test. Correlation coefficients were determined
using Spearman’s rank correlation test. P-values of o0.05 were
considered statistically significant.
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